Form 4: Gyre Therapeutics President Sells Shares Under 10b5-1 Trading Plan

Songjiang Ma, President of Gyre Therapeutics, sold shares of common stock on January 29th and 30th, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Songjiang Ma, the President of Gyre Therapeutics, sold 2,000 shares of common stock on January 29, 2025, at a weighted average price of $11.43 per share.
• He also sold 2,000 shares of common stock on January 30, 2025, at a weighted average price of $11.37 per share.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on September 13, 2024.
• Following these transactions, Mr. Ma directly owns no shares, but indirectly owns 2,891,138 shares through his spouse.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the stock sales were conducted under a pre-arranged trading plan, suggesting no specific negative outlook on the company's performance. It's a routine transaction.

Industry Context

Insider selling can sometimes be viewed negatively by the market, but the use of a 10b5-1 trading plan suggests the sales were pre-planned and not based on current inside information. It is common for executives to diversify their holdings or exercise stock options, leading to periodic sales.

Stakeholder Impact

• The stock sale could have a minor negative impact on shareholder sentiment, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates